FDA Office of Generic Drugs
Five members of the CDER's Biopharmaceutic Research Laboratory are moving to the generic drug office: BRL Branch Chief Gerald Shiu, research chemists Chuck Brownell and Hari Singh, staff fellow E. Asafu-Adjaye and lab technician Bill Worsley. Shiu will report to OGD Associate Director for Research Larry Lesko. In a Nov. 4 memo, OGD Director Roger Williams notes that the staff shift "provides OGD with a laboratory-based research facility to investigate current and anticipated regulatory issues".
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth